Accuray Incorporated (ARAY) Stock Analysis & Winston Score

Accuray makes radiation therapy machines used to treat cancer. Its two main products are the CyberKnife system, which uses robotic arms to deliver precise radiation to tumors, and the Radixact system, a more traditional radiation treatment platform. Hospitals and cancer treatment centers around the world are its primary customers. The company earns money by selling its machines to hospitals and then charging ongoing fees for service contracts, software upgrades, and replacement parts. Accuray operates globally, with a meaningful share of revenue coming from outside the United States, including China and Europe. It is a smaller player competing against much larger companies like Varian Medical Systems and Elekta, which limits its pricing power and scale advantages. The key risk is that its thin margins and negative operating income leave little room for error if sales slow or competition intensifies.